SAB Biotherapeutics Inc（SABS）資訊與事件SABSSAB Biotherapeutics Inc

SAB Biotherapeutics Reports Q3 Net Loss of $22.3M

Reports Q3 net loss $22.3M vs. net income $45.4M last year. Reports Q3 research and development expenses $18.1M vs. $9.0M last year. Reports cash, cash equivalents and investment securities $205.3M as of September 30. "We made solid progress advancing SAB-142 during the third quarter, driven by continued enthusiasm for the SAFEGUARD study. With the pediatric stepdown approved in September and our adult and adolescent cohorts fully enrolled and closed for screening, we remain on track to complete enrollment in the fourth quarter. The FDA's recent Fast Track designation is another important milestone, recognizing the significant unmet need in newly diagnosed Stage 3 type 1 diabetes and providing an opportunity for closer collaboration with the agency as we advance SAB-142 through clinical development. Our priorities are clear: complete SAFEGUARD enrollment, execute our clinical and regulatory strategy, and advance toward topline data in the second half of 2027. We believe SAB-142 has the potential to meaningfully change the treatment of type 1 diabetes, and we are focused on delivering on that promise," said Samuel Reich, CEO of SAB Biotherapeutics.

SAB Biotherapeutics Receives FDA Fast Track Designation

SAB Biotherapeutics announced that the FDA has granted Fast Track designation to SAB-142, a potentially disease-modifying immunotherapy being developed for the treatment of individuals with new-onset Stage 3 type 1 diabetes.

Emergent BioSolutions Signs $50M Agreement with SAB Biotherapeutics

Emergent BioSolutions (EBS) announced a multi-year agreement with SAB Biotherapeutics (SABS) to support the process development and manufacturing of SAB-142, SAB BIO's lead program in clinical development for autoimmune type 1 diabetes. The executed agreement is valued at approximately $50M, of which $36M is contingent on future regulatory approval and downstream milestones. Under the terms of the agreement, Emergent will provide end-to-end development and manufacturing services to SAB BIO that are compliant with current good manufacturing practices. These services will include process development and scale-up, technology and analytical method transfer, manufacturing for SAB-142's ongoing clinical program and commercial manufacturing services upon regulatory approval.